CLINICAL RESPONSE TO OPIOID ANALGESICS (CODEINE, FENTANYL, METHADONE, OXYCODONE, TRAMADOL): CLINICAL EXOME PANEL (Sec. & CNVs) – 3 genes
Delivery time
3-4 weeks
Sample
Blood
The Clinical Response to Opioid Analgesics panel focuses on the pharmacogenetic study of key genes involved in the metabolism and efficacy of opioid drugs used to treat acute and chronic pain. Genetic variants of opioid enzymes can modify the metabolic conversion of prodrugs, their active plasma concentration, and the risk of adverse effects such as respiratory depression or lack of analgesia. The study includes the genes CYP2D6, primarily responsible for the bioactivation of codeine, tramadol, and oxycodone; CYP3A4, involved in the metabolism of fentanyl and methadone; and CYP2B6, which participates in the clearance and interindividual variability in methadone response. Identifying polymorphisms in these genes allows for optimized analgesic selection, personalized dose adjustments, and a reduced risk of toxicity or therapeutic inefficacy. Key genes analyzed: CYP2D6, CYP3A4, and CYP2B6.
Other tests
Exome panel analysis of 29 genes - idiopathic pulmonary fibrosis and surfactant protein deficiency
990,00€
511 gene analysis - epilepsy (using exome sequencing)
1.495,00€
Exome analysis of AGXT, GRHPR, and HOGA1 genes - primary hyperoxaluria
690,00€